GoodRx Holdings, Inc. GDRX shares are trading higher after the company reported fourth-quarter FY23 results and issued first-quarter revenue guidance above estimates.
Revenue and adjusted revenue increased 7% Y/Y to $196.6 million, beating the consensus of $195.8 million.
Prescription transactions revenue increased 11% to $143.9 million, mainly driven by an 8% increase in Monthly Active Consumers and quarter-specific favorability related to certain client contracts.
GoodRx exited the quarter with over 7 million consumers of prescription-related offerings. Monthly Active Consumers were 6.4 million compared to 5.9 million a year ago.
Adjusted EBITDA rose to $57.3 million from $49.6 million, led by higher prescription transactions revenue, with margin expanding to 29.1% from 26.9%.
Adjusted EPS of $0.08 beat the consensus of $0.07.
As of December 31, 2023, GoodRx had cash and cash equivalents of $672.3 million and debt of $661.8 million.
Repurchase: The company repurchased shares worth $77.8 million in the quarter. As of December 31, 2023, GoodRx had $44.3 million of shares under its authorized share repurchase program.
On February 27, 2024, the board of directors approved a new stock repurchase program that authorized the repurchase of up to $450 million of shares.
Guidance: GoodRx expects FY24 revenue and adjusted revenue of $800 million versus a consensus of $790.53 million.
It sees first-quarter FY24 revenue and adjusted revenue of $195 million-$198 million versus the consensus of $192.91 million.
GoodRx forecasts an adjusted EBITDA of ~$250 million in FY24 and an adjusted EBITDA margin in the high 20% range, potentially up to 30% in the first quarter.
Also Read: Prescription Drug Discount Provider GoodRx Expects To Build Momentum In 2024, Stock Soars
Price Action: GDRX shares are up 17.2% at $7.58 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.